2025 YEAR IN REVIEW
For investors audiences
This page is intended for U.S. residents only
Regeneron leadership, including it’s co-Founders, reflect on 2025 and the opportunities ahead.
Science Without Limits
With 15 approved or authorized treatments developed in-house and nearly 50 pipeline candidates, Regeneron has built an unmatched track-record of translating science into medicines for patients in need – and 2025 strengthened that momentum.
Sustained investment in our science and capabilities is driving real world impact, from advancing our industry-leading pipeline and integrating technologies that accelerate drug discovery to expanding our manufacturing footprint. Fueled by the dedication of thousands of colleagues worldwide, Regeneron is well-positioned for enduring growth.
To Our Fellow Shareholders,
Regeneron’s future is more promising than ever, and we remain true to what has set us apart from the beginning: a deep scientific focus, a commitment to developing novel, disruptive technologies that deliver real-world impact, and a relentless drive to continue to push the boundaries that currently limit progress and patient benefit.
With a high-performing commercial portfolio, a highly productive research and development (“R&D”) effort that has generated nearly 50 novel drug candidates currently in clinical development, disciplined capital allocation, and a talented workforce, we are poised to deliver multiple new breakthrough medicines in the coming years and help even more people in need.
With a high-performing commercial portfolio, a highly productive research and development (“R&D”) effort that has generated nearly 50 novel drug candidates currently in clinical development, disciplined capital allocation, and a talented workforce, we are poised to deliver multiple new breakthrough medicines in the coming years and help even more people in need.
Leonard S. Schleifer, MD, PhD
Board co-Chair, President and Chief Executive Officer
George D. Yancopoulos, MD, PhD
Board co-Chair, President and Chief Scientific Officer
Regeneron by the numbers
(as of April 2026, unless noted otherwise)
15
medicines approved in the United States or other countries
~50
countries with clinical trials
50%
of colleagues volunteered globally - twice the average participation rate (CECP 2025)
12
approvals, including 1 new product approval and 11 approvals for additional indications or populations for existing products in the U.S., European Union and Japan in 2025
83K+
eligible patients given ~$2.8B1 worth of medicine at no cost through our products’ patient assistance programs in 2025
Nearly
50
50
product candidates in clinical development across multiple therapeutic areas, 18 of which are in late-stage programs
3M+
exomes sequenced to date by Regeneron Genetics Center®
$9B
committed to ongoing/upcoming U.S. manufacturing and R&D infrastructure expansion
15.4K+
Regeneron colleagues worldwide
4M+
students supported by Regeneron STEM initiatives since 2020
~$6.6B
anticipated R&D investment in 2026
15
medicines approved in the United States or other countries
~50
countries with clinical trials
50%
of colleagues volunteered globally - twice the average participation rate (CECP 2025)
12
approvals, including 1 new product approval and 11 approvals for additional indications or populations for existing products in the U.S., European Union and Japan in 2025
83K+
eligible patients given ~$2.8B1 worth of medicine at no cost through our products’ patient assistance programs in 2025
Nearly
50
50
product candidates in clinical development across multiple therapeutic areas, 18 of which are in late-stage programs
3M+
exomes sequenced to date by Regeneron Genetics Center®
$9B
committed to ongoing/upcoming U.S. manufacturing and R&D infrastructure expansion
15.4K+
Regeneron colleagues worldwide
4M+
students supported by Regeneron STEM initiatives since 2020
~$6.6B
anticipated R&D investment in 2026
- Based on 2025 year-end wholesale acquisition cost.
Business Snapshot
KEY 2025 FINANCIAL HIGHLIGHTS
$14.3B
Total revenue
$5.9B
Total R&D investment
$3.8B
Returned to shareholders through share repurchases and dividends in 2025
YOY TOTAL REVENUE
| Year | Revenue (USD, Billions) |
|---|---|
| 2018 | 5.1 |
| 2019 | 6.6 |
| 2020 | 8.5 |
| 2021 | 16.1 |
| 2022 | 12.2 |
| 2023 | 13.1 |
| 2024 | 14.2 |
| 2025 | 14.3 |
